‹ Back to screener

COHANCE.NS Cohance Lifesciences Ltd.

Healthcare

Price history

2025-08-21 ₹898.05
2026-08-21 ₹460.25
Change over window -48.75%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 49.4%
Trailing 20-day average 43.3%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 272982 134795 49.38%
2026-08-27 308834 122117 39.54%
2026-08-26 1018072 366992 36.05%
2026-08-25 635089 295342 46.50%
2026-08-24 909426 395610 43.50%
2026-08-21 1638869 625779 38.18%
2026-08-20 6561470 1364462 20.80%
2026-08-19 282289 123884 43.89%
2026-08-18 1507812 431553 28.62%
2026-08-17 1708901 506502 29.64%
2026-08-14 388718 198405 51.04%
2026-08-13 605174 291523 48.17%
2026-08-12 517907 279758 54.02%
2026-08-11 2268116 717244 31.62%
2026-08-10 1368704 695912 50.84%
2026-08-07 1985052 1505136 75.82%
2026-08-06 6018027 1358172 22.57%
2026-08-05 365514 194894 53.32%
2026-08-04 247065 128555 52.03%
2026-08-03 312974 157041 50.18%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers COHANCE.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
19 Sep 2025 Jusmiral Holdings Limited Promoters Sell - 34148000 30938088000 24.15% XBRL
12 May 2025 Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri Director Buy Scheme of Amalgamation/Merger/Demerger/Arrangement 713259 713259 0.19% XBRL
12 May 2025 Jusmiral Holdings Limited Promoters Buy Scheme of Amalgamation/Merger/Demerger/Arrangement 126538578 126538578 33.08% XBRL
30 Sep 2023 JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED Promoters Sell Off Market 127537043 63130836285 9.90% XBRL
14 Aug 2023 PADMAJA J.A.S Immediate relative Sell Market Sale 28000 14049630 0.00% XBRL
17 Feb 2023 PADMAJA J.A.S Immediate relative Sell Market Sale 7000 3375726 0.01% XBRL
02 Sep 2020 PADMAJA J.A.S Immediate relative Buy Market Purchase 5000 3203198 0.01% XBRL
31 Aug 2020 PADMAJA J.A.S Immediate relative Buy Market Purchase 2500 1720386 0.01% XBRL
27 Aug 2020 PADMAJA J.A.S Immediate relative Buy Market Purchase 5000 3514022 0.01% XBRL
24 Aug 2020 PADMAJA J.A.S Immediate relative Buy Market Purchase 5000 3428711 0.00% XBRL
04 Jul 2020 PADMA KUMAR R Employees/Designated Employees Buy Market Purchase 10000 4703067 0.10% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers COHANCE.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹463.00 INR (live) · fetched 2026-08-23 21:43 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Ratios

P/E
98.84
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹463.00 / (₹1,792,300,000 / 382,600,000 shares) = ₹463.00 / ₹4.68 EPS
FY2025-26 · Annual filing
ROE
4.58%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹1,792,300,000 / ₹39,112,900,000 = 4.58%
FY2025-26 · Annual filing
Debt/Equity
0.04
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹1,696,700,000 / ₹39,112,900,000 = 0.04
FY2025-26 · Annual filing
Current Ratio
2.78
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹17,962,600,000 / ₹6,459,300,000 = 2.78
FY2025-26 · Annual filing
ROCE
6.71%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹2,737,500,000 / (₹39,112,900,000 + ₹1,696,700,000) = 6.71%
FY2025-26 · Annual filing
Dividend Yield
0.00%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹0 / 382,600,000 shares) / ₹463.00 = ₹0.00 / ₹463.00
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 19.2%
Net Profit (3y) N/A
Revenue (5y, 3.0y actual) 19.2%
Net Profit (5y) N/A
Revenue (10y, 3.0y actual) 19.2%
Net Profit (10y) N/A

Operating Margin Trend

Eroding

FY2022-23 42.2%
FY2023-24 39.3%
FY2024-25 29.7%
FY2025-26 12.1%

ROCE Trajectory

FY2022-23 31.3%
FY2023-24 19.8%
FY2024-25 18.6%
FY2025-26 6.5%

Earnings Quality

Net profit or operating cash flow was zero or negative in the base or latest year — a growth-rate comparison isn't defined across a sign change.

Sector-Relative Percentile (Healthcare)

ROE 11th
ROCE 7th
Debt/Equity 63th
P/E 13th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q2 FY2023-24 Q3 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹231.05 Cr. ₹219.82 Cr. ₹230.69 Cr. ₹257.72 Cr. ₹307.15 Cr. ₹402.02 Cr. ₹549.31 Cr. ₹544.55 Cr. ₹619.12 Cr. ₹422.26 Cr. RevenueFromOperations
Net Profit ₹79.56 Cr. ₹46.75 Cr. ₹60.76 Cr. ₹82.21 Cr. incl. minority ₹81.98 Cr. ₹82.88 Cr. incl. minority ₹83.29 Cr. ₹42.01 Cr. incl. minority ₹38.73 Cr. ₹48.88 Cr. incl. minority ₹46.40 Cr. ₹36.72 Cr. incl. minority ₹29.02 Cr. ₹19.55 Cr. incl. minority ₹8.31 Cr. ₹-24.12 Cr. incl. minority ₹-45.19 Cr. ProfitLossForPeriod

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers COHANCE.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent1792300000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital382600000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets17962600000.0
CurrentLiabilities6459300000.0
EquityAttributableToOwnersOfParent39112900000.0
BorrowingsCurrent + BorrowingsNoncurrent1696700000.0

My notes